Scientist Solutions: International Life Science Community By Scientists For Scientists
Home » Societies » The Biotech Research Society of India Forum

The Biotech Research Society of India Forum

Thanks to our sponsors who make this site possible
Welcome Members and guests. Our Forum is brought to you through our partnership with Scientist Solu- which manages these pages to promote the free exchange of useful scientific information. We
encourage you to dive in and join the conversation!

How do I use this forum?
Registered members can create new topics and reply to topics from other users. To learn more about s-
uccessful posting in the forums Click Here. Subscribing to Society Sub-forums will keep you informed
and involved.
Disclaimer - The The Biotech Research Society of India Society supports the free exchange of scientific information, but is not responsible or liable for comments made in public forums such as this one. Topics and posts deemed unsuitable will be moderated and removed.

The Biotech Research Society of India Subforums

RSS Feed
Sub-forumsTopics  Replies  ViewsLast Post

Strategies to Identify Drug Targets/Biomarkers

22 23 36073

Urgent Dilution problem! Please hel ...

by Saluferkimo
May 21, 2015, 15:24 PM

Target Validation Techniques

Target Validation Techniques
9 9 24550


by skarthikumar
Nov 09, 2012, 11:02 AM


Extent and rate of absorption, distribution, metabolism and excretion ( ADME)
18 46 53353


by Debbie Reed Bietz
Jun 25, 2012, 11:25 AM

Bioprocessing/Scale Up and Isolation

Fermentation, cell culture, expression, and recovery
22 27 37563

isolating dna from spotted on filte ...

by Pippuri
May 04, 2015, 16:26 PM

Good Manufacturing/Validation Practice (GMP/GVP)

Control and management
24 51 51892

Performance Qualification (PQ) of L ...

by Eibhor
Aug 17, 2015, 21:01 PM


Pharmacology equipment
18 49 47272

How to choose your system Fiber opt ...

by Idealphotonics
Oct 05, 2015, 6:41 AM

Assay Development & Protocols

Also, remember to visit the protocols tab on the homepage toolbar
48 46 59901

Xanthine Oxidase Inhibitory Assay

by Paye
Feb 27, 2012, 20:34 PM

Society Overview

The aims & objectives of the Biotech Research Society [BRSI] are:
  • To promote the R&D in biotechnology in India
  • To bring interaction between the academic institutes and the biotech industries, interact with the industries and help them in resolving their problems, as well make them aware with the latest developments in the biotech sector
  • To provide and arrange the training in biotechnology, dissemination of biotech knowledge through the organization of the lectures, seminars and symposia on the scientific programmes and societal missions.

Contact Society Forum Organizer
Society Organizer: Ashok Pandey

Click here to
Become a member & join our
community (It's easy & free)
Already a member? Please log in
User Name  
Forget Password?
News Feeds from
BioTech News
Biotech news continually updated from thousands of sources around the net.

Fortress Biotech Inc was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 3,717,879 shares, an increase of 2.6% from the March 15th total of 3,623,041 shares.

Wall Street brokerages expect Vanda Pharmaceuticals Inc. to report $38.35 million in sales for the current quarter, according to Zacks . Two analysts have issued estimates for Vanda Pharmaceuticals' earnings.

Shares of Signet Jewelers Ltd. and Bristol-Myers Squibb have had a rough year. Has the market gone too far, or are these value stocks actually value traps? The past year has been tough on retail stocks, but investors who like dividends and value might have noticed some big yields in this space.

Media stories about Eli Lilly and have trended somewhat positive recently, according to Alpha One. The research firm, a unit of Accern, ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time.

Oakworth Capital Inc. held its stake in Quest Diagnostics Inc during the first quarter, Holdings Channel reports. The firm owned 2,608 shares of the medical research company's stock at the end of the first quarter.

Sales of top-selling Revlimid grew 20% year over year as doctors continue to increase the use of the drug and patients stay on it longer. Sales of Abraxane, which have been relatively stalled for awhile, rose 5% year over year with all of the growth coming from outside the U.S. The one issue came from Otezla, which produced sales growth of 24% year over year.

A 12-member Philadelphia jury handed up a $20 million verdict-including $17.5 million in punitive damages-against Johnson & Johnson subsidiary Ethicon in the third pelvic mesh case to go to trial in the city. The verdict in Ethicon v.

Last week, Apotex filed a Citizen Petition requesting that FDA "take certain actions to ensure a robust approval process" for proposed biosimilars to Amgen's Neulasta . Among its requests, Apotex asks that FDA require each biosimilar applicant to conduct comparative clinical efficacy studies, including pharmacokinetics, pharmacodynamics, and immunogenicity studies, in at least one intended patient population, rather than conducting such studies only in healthy subjects.

Two experimental therapies hatched in the labs of Massachusetts biotechs won Food and Drug Administration approval Friday to be sold in the United States. Federal regulators used an accelerated approval process to green-light a targeted small-molecule lung cancer drug, developed by Ariad Pharmaceuticals Inc. before the Cambridge-based company was sold earlier this year to Japan's Takeda Pharmaceuticals Inc. Also approved, two months before the FDA's scheduled decision date, was a hormone treatment developed by Radius Health Inc .

Danish pharmaceutical giant Novo Nordisk is being accused of engaging in a "white coat marketing scheme" to entice doctors to prescribe three of its diabetes drugs - NovoLog, Levimir, and Victoza. Together these three drugs made Novo Nordisk $6 billion in sales in 2013, comprising 10% of the company's worldwide sales for the year, according to the complaint.

A manufacturing issue has created a shortage of the only vaccine licensed in the U.S. The Centers for Disease Control and Prevention said Friday that doses could run out as early as next month. Officials are bringing in another vaccine that's used in other countries but it will be available at far fewer clinics.

Wainwright will act as sales agent for any sales made under the new ATM program. The Common Shares will be sold at market prices prevailing at the time of the sale of the Common Shares, and, as a result, prices may vary.

The firm presently has a $312.67 price objective on the biotechnology company's stock. Vetr 's price target would suggest a potential upside of 13.01% from the company's current price.

News coverage about GenVec has been trending positive on Thursday, according to Alpha One. The research group, a service of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time.

GlaxoSmithKline plc posted its quarterly earnings data on Wednesday. The pharmaceutical company reported $0.62 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.62.

The second-quarter 2017 cash dividend will be the 314th consecutive quarterly dividend paid by Pfizer. "In 2016, we returned nearly $12.3 billion to shareholders through dividends and share repurchases," said Ian Read, chairman and chief executive officer.

U.S. biotechnology company Celgene Corp reported lower-than-expected sales, hurt in part by soft demand for its psoriasis treatment even as sales of its flagship drug Revlimid beat estimates. The company's cancer treatment Abraxane generated sales of $236 million and its psoriasis drug Otezla brought in $242 million.

Thank You to Our Sponsor